BrightStar 💫 (MDACC; Elamin et al.) is one of the most informative datasets we have on pairing brigatinib with local consolidative therapy (LCT) in ALK-rearranged mNSCLC.

Here’s a walkthrough of the final analysis and why it matters for both oligo & poly disease.

#WCLC25 🧵


Trial Overview
Phase I | TKI-naïve ALK+ NSCLC
Induction: 8 weeks of brigatinib → LCT for all residual disease.
Eligible whether oligo or poly, as long as at least 1 site remained after induction.
Baseline:
• 82% polymetastatic (>3 sites)
• 41% brain metastases
• LCT: RT (27), surgery (3), surgery+RT (2)
• 94% ultimately proceeded to LCT
This is very much a real-world metastatic cohort.

🚨NEW in @CACancerJournal:

A comprehensive review of advances in hepatocellular carcinoma (#HCC) therapy. From surgery to IR to SBRT to immunotherapy, this is your clinical update

🧵

@NiuSanford @nbn426 @KrishanJethwa @safaviaa @ldawsonmd @aallam_mo @freddyeescorcia @5_utr

https://twitter.com/SyedAAhmad5/status/1932377269290287146

1/ HCC is now the 3rd leading cause of cancer death worldwide. Despite surveillance, >70% of patients are diagnosed at an advanced stage, highlighting the urgent need for therapeutic advances.

🧵1/
Big news in unresectable stage III NSCLC.

The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT).

Early results are promising. Let’s dig in. 🔍

#LungCancer #RadOnc #ASCO25
2/
📌 Background:
Patients with bulky, unresectable stage III NSCLC remain a major clinical challenge. Prior retrospective data hinted that induction NAC-ICI before CRT might help. InTRist is the first randomized phase II trial to formally test this.

🧵1/

🚨New case report out in Cureus:

Face the Pain: Radiobiological and Clinical Considerations of Re-radiosurgery to the Trigeminal Nerve

👉 A deep dive into a unique case of medically refractory TGN in the setting of a petroclival meningioma.

🔗 doi.org/10.7759/cureus… 2/
An 81-year-old woman was treated at an OSH for a trigeminally-symptomatic petroclival meningioma, to 25 Gy in 5 fx.

Despite good tumor control, facial pain persisted, and surgery wasn’t an option.

So… what now?

🚨 We’re hiring not one but TWO medical oncologists in Parkersburg, WV, a welcoming community with real need, a big heart, and a team that’s ready to support you. A chance to truly make a difference in a community of need:
wvumedicine.wd1.myworkdayjobs.com/UHA/job/Camden… This is a hospital-based community cancer center with a robust clinical trials program, cutting-edge tech, and deep roots to our community. In recent years, our care has transformed, and so has our impact.

wvumedicine.org/camden-clark/s…

1/ Treating hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has always been challenging. New research compares two approaches—surgery and stereotactic body radiotherapy (SBRT)—providing fresh perspectives on how we care for these patients.

Let’s dive in. 🧵


2/ This study used propensity score matching to ensure fair comparisons between the two groups. The primary outcome was overall survival (OS), with secondary outcomes including local control and distant recurrence rates.

Here’s what they found: 🧑‍⚕️👇

Fabio Arcidiacono: Five year survival and safety outcomes from the START-NEW-ERA non-randomized phase II trial #ESTRO24 #LCSM #radonc

Is there a role for Local Tx of the Primary Tumor for Patients with Metastatic Cancer?

🚫Many studies demonstrate no benefit.
📌We performed a MetaAnalysis to evaluate the average effect of Local Tx across various tumors.

A thread🧵#AMSM #PRIMETX
redjournal.org/article/S0360-…

1/25 Critics of Local Tx to the Primary Tumor

📌 Many providers think local control of the primary tumor in the setting of M1 dz is akin to “closing the barn door after the horse has bolted”
📌 Ian Tannock wrote a fantastic article on this back in 2000.

pubmed.ncbi.nlm.nih.gov/11759650/

2/